Alzheimer and gene therapy in two minutes

Tetraneuron

First Spanish Biotech Start-up at the Johnson & Johnson European Innovation Centre

Tetraneuron was founded as a spin-off from the Cajal Institute belonging to the Spanish Scientific Research Council (CSIC).
We are developing an innovative and disruptive multifactorial gene therapy to treat Alzheimer’s disease, as well as a biomarker for early detection of this terrible disease.

About us

Our History

Lines of research

Tetraneuron is actively working on two lines of research, both derived from the phosphorylation of E2F4 during the earliest stages of Alzheimer’s disease.

Find out more

Multifactorial gene therapy

Gene therapy based on E2F4DN. A promising approach for Alzheimer’s disease.

More info

Biomarker for early diagnosis

A method to determine the risk of developing Alzheimer’s disease at an early stage.

More info

Scientific articles

See all

Our team

The scientific team is made up of personnel with over 30 years’ experience in neuroscience and executives from biopharmaceutical companies as associates.

Contact

New at Tetraneuron

Collaborating Institutions and Societies